Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
DMRA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 22, 2026
Report Source: 2026 1st Quarter Report
Damora Therapeutics Inc. Stock Analysis DMRA
United States Health Care Small Cap Report: Damora Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2020-10-29. The firm is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. The company offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.
Read More Damora Therapeutics Inc (DMRA) Chart
Key Statistics of Damora Therapeutics Inc (DMRA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$23.21Volume
325.73KP/E Ratio (TTM)
-52 Week Range
Market Cap
1.53BAvg. Volume
467.20KDividend Yield
-Financial Metrics & Statements of Damora Therapeutics Inc (DMRA)
FAQ's for Damora Therapeutics Inc (DMRA)
- According to Musaffa’s Shariah screening methodology, Damora Therapeutics Inc (DMRA) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Damora Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Damora Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Damora Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Damora Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Damora Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.